Influenza
Conditions
Keywords
Influenza, vaccination, Emergency Department
Brief summary
Randomized controlled trial of influenza vaccination versus referral for vaccination in the Emergency department. Is the Emergency Department an effective venue for vaccination for influenza? Does vaccination for influenza in the Emergency Department change the rates of influenza, influenza-like-illness or medical provider visits when compared with patient referred for vaccination in the community?
Detailed description
This study is a prospective randomized, controlled trial of influenza vaccination vs referral for influenza vaccination in the Emergency Department. Subjects are either offered vaccination or education regarding vaccination and a list of community providers. At a four-month follow up, rates of influenza, influenza-like illness and number of medical provider visits are determined.
Interventions
DRUGInfluenza Vaccination
0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
BEHAVIORALEducation and referral
Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
Sponsors
University of Arizona
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Unvaccinated patients presenting to the Emergency Department aged 6 months or more who have at least one high risk attribute: * Age 6-59 months or \>50 years * Pregnant * Health care worker * Aged 6 months-18 years on chronic aspirin therapy * Comorbidity (cardiovascular disease, pulmonary disease, metabolic disease, renal disease, hepatic disease, seizures, neuromuscular disease, cognitive dysfunction, or any reason to have had regular medical follow up or hospitalization in the preceding year) * Household contact or caregiver of someone with at least one high risk attribute
Exclusion criteria
* Prior vaccination * History of Guillan-Barre syndrome within 6 weeks of prior influenza vaccination * Allergy to influenza vaccination or eggs * Age \< 6 months old * Fever with more than minor illness * Hospitalization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaccination status | 4 months |
Secondary
| Measure | Time frame |
|---|---|
| Influenza rate | 4 months |
| Influenza-like illness rate | 4 months |
| Visits to medical providers | 4 months |
Countries
United States
Outcome results
None listed